A Fast and Sensitive LC/MS/MS Method for the Quantitation and Confirmation of 30 Benzodiazepines and Nonbenzodiazepine Hypnotics in Forensic Urine Samples

Cliquid[™] Drug Screen & Quant Software for Routine Forensic Toxicology



Overview

A fast and sensitive LC/MS/MS method for the detection of 27 benzodiazepines and 3 nonbenzodiazepine hypnotics in forensic urine samples was developed. Quantitation and confirmation of all compounds is possible at least one order of magnitude lower than the cut-off level of 100ng/mL.

The developed method is preconfigured in Cliquid[™] Drug Screen & Quant Software which enables the use of this method in forensic toxicology or clinical research with automatic reporting of quantitative results and MRM ratio confirmation.

Introduction

Benzodiazepines and other nonbenzodiazepine hypnotics, such as Zaleplon, Zolpidem, and Zopiclone are widely prescribed psychoactive drugs for the treatment of anxiety and sleep disorders. Frequently these substances lead to dependence and abuse and some of them can affect judgment and behavior. Thus these compounds are of great interest in forensic, toxicological and clinical research laboratories.

The screening for benzodiazepines with immunoassay tests does not provide enough sensitivity and specificity. The analysis using Gas Chromatography (GC) with different detectors is difficult or impossible because of thermal instability and requires time consuming derivatization and clean-up steps. Finally Liquid Chromatography (LC) with UV detection can not detect benzodiazepines at required concentration levels and lacks in selectivity.

LC coupled to Tandem Mass Spectrometric detection (MS/MS) with Electrospray lonization (ESI) is the ideal technology for the analysis of polar and thermally labile drugs and their metabolites with highest sensitivity and specificity after a fast and simple sample preparation step. The developed LC/MS/MS method detects 30 analytes in a single chromatographic run using two Multiple Reaction Monitoring (MRM) transitions



3200 QTRAP® LC/MS/MS System

to allow quantitation and confirmation. The detection of such a high number of transitions without sensitivity loss is possible due to the Linear Accelerator (LINAC[®]) collision cell of the 3200 QTRAP[®] LC/MS/MS System.

Experimental

Sample Preparation

 100μ L of internal standard solution (1μ g/mL D₅-Diazepam and D₃-Doxepin) were added to 100μ L of urine sample. After shaking 800μ L water (LC grade) were added. The diluted sample was centrifuged and directly injected into the LC/MS/MS system.

Alternatively, urine samples can be hydrolyzed using ß-glucuronidase prior to analysis to detect benzodiazepine metabolites together with the precursor drugs.^{1,2,3}

Liquid Chromatography

LC separation was carried out using a Shimadzu Prominence LC system equipped with 2 pumps, semi-micro gradient mixer, column oven and autosampler. An analytical Allure® PFP propyl column (Restek, Bellefonte, PA) 50x2.1mm with 5µm particles and 10x2.1 guard column was used with a mobile phase of (A) water with 0.2% formic acid and 2mM ammonium formate and (B) acetonitrile with 0.2% formic acid and 2mM ammonium formate. The gradient conditions are described in Table 1. The LC column was used at a temperature of 40°C and a volume of 30µL was injected.

Mass Spectrometry

MS/MS detection was carried out on a 3200 QTRAP[®] LC/MS/MS system equipped with a Turbo V[™] source with Electrospray lonization probe. The detected MRM transitions with corresponding compound depending parameters are given in Table 2 (Declustering Potential; DP and Collision Energy; CE). The first MRM was used to quantify the analyte while




Figure 1. Chromatogram of a mix of drugs of 30 benzodiazepines and nonbenzodiazepine hypnotics spiked into a urine sample and analyzed by LC/MS/MS.

the ratio to the second MRM was used for confirmation. All MRM transitions were detected with a dwell time of 25ms and a pause time of 5ms.

Cliquid[™] Drug Screen & Quant Software

The developed method is preconfigured in Cliquid[™] Drug Screen & Quant Software.

Cliquid Software provides a simple, four step workflow using preconfigured tests and report styles to make the operation of LC/MS/MS technology for routine forensic and toxicological testing easier. All presented results of forensic case samples are generated automatically and instantly after acquisition.

Results

An example chromatogram of all 30 benzodiazepines and nonbenzodiazepine hypnotics spiked into urine and analyzed by LC/MS/MS after sample preparation is shown in Figure 1. A list

TABLE 1. LC GRADIENT WITH (A) WATER + 0.2% FORMIC ACID + 2mM AMMONIUMFORMATE AND (B) ACETONITRILE + 0.2% FORMIC ACID + 2mM AMMONIUM FORMATE

Time (min)	Flow (mL/min)	% A	% B
0	0.5	90	10
10	1.0	10	90
15	1.0	10	90
15.5	0.5	90	10
17.5	0.5	90	10

of all retention times of all substances can be found in Table 1. The superior sensitivity of the method is highlighted by extracted MRM chromatograms presented in Figure 2. Signal-to-Noise varies depending on the ionization and fragmentation efficiency of each analyte. Thus Limits of Quantitation (LOQ) are different. However, all targeted compounds can be quantified in urine samples after a dilution step (10x) at a concentration of at least 10ng/ mL. All LOQ values are listed in Table 2. The Coefficients of Variation (% CV) of all compounds below 10% indicate that the developed method allows reproducible quantitation even at low concentration levels.

The high selectivity of MRM detection allows compound specific detection without interference of urine matrix or other xenobiotics being present in the sample. Possible ion suppression effects during ESI caused by co-eluting matrix components were investigated using pooled urine. Figure 3 and 4 show that matrix effects depend on retention times and that they can be minimized or completely eliminated by dilution of the urine sample. For example, the signal of 7-Aminoclonazepam (t_R=3.3min) had strong matrix interference requiring dilution by a factor of 10 to minimize the ion suppression to less than 20% while the signal of Zolpidem (t_R=7.3min) was not effected by matrix at all.

Based on these studies a dilution factor of 10 was chosen to minimize matrix effects to a level of less than 20% for all analytes.




Figure 2. High sensitivity and selectivity of LC/MS/MS detection of 10ng/mL of Benzodiazepines and nonbenzodiazepine hypnotics in urine samples after sample preparation (blue trace: quantifier MRM and red trace: qualifier MRM).

Automatic Data Processing

The developed method for the quantitation and confirmation of benzodiazepines and nonbenzodiazepine hypnotics is built into Cliquid[™] Drug Screen & Quant Software.⁴ Preconfigured report styles allow an automatic reporting regarding forensic guidelines. An example report of a forensic urine sample tested positive for Diazepam (1.6ng/mL), Nordiazepam (670ng/mL), and Temazepam (470ng/ mL) is shown in Figure 5. The yellow highlighting in the results table indicates a positive confirmation based on the detected MRM ratio.

Summary

The developed LC/MS/MS method for the quantitation and confirmation of 27 benzodiazepines and 3 nonbenzodiazepine hypnotics was successfully applied for the analysis of forensic case urine samples. The targeted compounds had Limits of Quantitation between 0.1 and 10ng/mL in urine after simple and fast sample preparation which consists of the addition of internal standards and 1/10 dilution. The dilution step was proven to be sufficient to minimize matrix effects during ionization to allow an accurate and reproducible quantitation.

The developed LC/MS/MS method is preconfigured in Cliquid[™] Drug Screen & Quant Software to allow testing in routine forensic toxicology or clinical research with automatic reporting of quantitative results and MRM ratio confirmation.

Future developments will include the detection of glucuronide metabolites of benzodiazepines by either extended sample preparation with hydrolysis or the direct detection of MRM transitions of respective metabolites.




Figure 3. Minimizing ion suppression of 7-Aminoclonazepam (3.3min), Lorazepam (4.4min), Diazepam (5.5min), Prazepam (6.1min), and Zolpidem (7.3min) by dilution of urine.






TABLE 2. MULTIPLE REACTION MONITORING (MRM) TRANSITIONS, COMPOUND DEPENDANT PARAMETERS, AND RETENTION TIMES, LIMIT OF QUANTITATION (LOQ) IN URINE BASED ON THE QUALIFIER MRM TRANSITION, AND COEFFICIENT OF VARIATION (n=3) OF ALL DETECTED SUBSTANCES

Substance	Q1 (amu)	Q3 (amu) quantifier	Q 3 (amu) qualifier	DP (V)	CE (V) quantifier	CE (V) qualifier	Retention time (min)	LOQ ng/mL (S/N=6)	% CV (10ng/mL)
2-Hydroxyethylflurazepam	333.1	211.2	109.0	56	51	41	4.5	1	6.3
7-Aminoclonazepam	286.1	121.0	222.2	46	41	35	3.3	0.5	0.6
7-Aminoflunitrazepam	284.1	135.1	226.0	51	39	49	3.8	0.5	1.6
7-Aminonitrazepam	252.1	121.1	94.0	51	35	53	3.2	1	4.3
Alprazolam	309.1	205.1	281.1	56	53	35	4.8	1	3.1
Bromazepam	316.0/318.0	182.1	182.1	51	45	45	3.8	5	7.7
Chlordiazepoxide	300.1	227.1	283.2	36	31	21	6.0	5	3.8
Clobazam	301.1	259.1	224.3	46	29	47	4.9	1	2.9
Clonazepam	316.0	270.2	214.0	56	41	51	4.7	2	8.3
Desalkylflurazepam	289.1	140.1	226.1	71	41	39	4.7	2	8.5
Desmethylflunitrazepam	300.1	254.2	198.2	56	35	51	4.5	2	7.9
Diazepam	285.0	193.2	154.1	55	41	37	5.5	1	10.1
Estazolam	295.0	205.0	267.1	51	53	31	4.4	2	7.0
Flunitrazepam	314.0	268.1	239.1	56	35	49	5.0	1	4.3
Flurazepam	388.2	315.1	317.1	36	27	27	8.5	0.1	3.1
α -Hydroxyalprazolam	325.1	297.2	204.9	51	31	59	4.1	2	7.3
lpha-Hydroxytriazolam	359.0	239.2	176.0	61	63	37	4.1	5	6.5
Lorazepam	321.0/323.1	275.0	277.0	41	31	27	4.3	5	7.9
Lormetazepam	335.0/337.1	289.0	291.1	41	29	29	4.8	2	6.4
Medazepam	271.0	91.1	207.3	46	41	39	9.0	2	5.4
Midazolam	326.1	291.3	222.0	56	33	63	7.9	0.5	6.0
Nitrazepam	282.0	236.1	180.2	71	35	51	4.6	2	7.7
Nordiazepam	271.1	140.2	164.9	46	37	35	5.0	2	6.7
Oxazepam	287.0	241.1	268.9	41	27	19	4.2	10	7.6
Prazepam	325.1	271.1	140.0	81	31	53	6.1	2	6.6
Temazepam	301.1/303.1	255.1	257.2	35	30	30	4.7	5	3.9
Triazolam	343.0	238.9	314.9	61	53	37	4.7	1	1.7
Zaleplon	306.2	236.3	264.2	56	35	27	4.4	0.5	10.2
Zolpidem	308.2	235.1	236.1	56	39	35	7.4	0.2	1.8
Zopiclone	389.1	244.8	217.0	16	25	41	5.4	1	5.3
D ₅ -Diazepam	290.1	198.2	-	55	41	-	5.4	-	-
D ₃ -Doxepine	283.0	107.1	-	41	35	-	9.1	_	-

	2 1.0 Diosystem	SI CMDS SCIEX	ARB Applied Created with Analyst Reporter							AB Biosystems MDS SCIEX			
	uta File esult Table	DataCluart Benooliazepines with blie 2007_06_22_105508_Benzodazepines.reb							Peak Review				
	source Morea	11110 000	Interfor V	264			1	,	1	1	1	14	13
					wa		- L.,	mar al the a	What			1 1 1 1 1 1	
	equisition Nethod									7.Aminoclonatenant	7.Aminoclonazenaen 2	7.Aminofluminazoon I	1นี้สรีผูน 7.Aninefferinate
	jection Vial	10	Weight to 1	folume 1.00			10000	33.1/2112 ans	333.1/109.0 ame	286.U121.0 amo	286.1/222.2 ans	284.9135.1 ans	284.9226.0 at
	esults Summary									1			
	Analyte Peak Kame	Analyte RT	Expected RT	Calculated Concentration (ng/mL)	Ion Ratio	Confirms						Transformering	Bromatropan 318.0/182.1 at
	Hydroxyethyffurazepam 1	0.00	4.46	No Peak	No Peak ()		2	SETTING	102.094.0326	Piece	904.0281.1 and	anov (80.1 arts	318.0182.1 a
	Aminocionazepam 1	0.00	3.14	No Peak	No Peak ()		3			3			3
	Arrenodonazapam 2	0.00	3.14	No Peak	No Peak (0.6587)		Ē		1	13	h i	14	13
			3.75		No Peak () No Peak (0.2958)		E		1	1.6	н.	11	
	Aminonitrazepant 1	0.00	2.80	No Peak	No Peak ()		3	hadimonide 1			Jassesseretiggfishatereene Chinane 2	Anteritaly deserves	1. Construction of
					No Peor Ci		3	00.1/227.1 ans	300.1/283.2 arts	391.1/259.1 amo	301.1/2243 ans	316.0/270.2 ans	Clonatopan 316.0/214.0 at
Damba 1 Operation Operation <th< td=""><td>prezolern 2</td><td></td><td>4,74</td><td>No Peak</td><td>No Peak (1.0351)</td><td></td><td>-</td><td></td><td>1</td><td>1 200</td><td>1</td><td>2 1</td><td>1</td></th<>	prezolern 2		4,74	No Peak	No Peak (1.0351)		-		1	1 200	1	2 1	1
Introduction 1 Op/D		0.00			No Peak ()						Li I		
Constants Constants <t< td=""><td></td><td>5.99</td><td>5.67</td><td>3910.00</td><td>0</td><td></td><td>1</td><td></td><td></td><td>19</td><td></td><td>14</td><td>19</td></t<>		5.99	5.67	3910.00	0		1			19		14	19
South 1 South 2 South 2 <t< td=""><td>hrond size posside 2</td><td>0.00</td><td>5.70</td><td>No Peak</td><td>No Peak (1.5332)</td><td></td><td></td><td></td><td>In the second</td><td>Tenzaleza la se a</td><td>Landaharre</td><td>hand the star</td><td>I have been a</td></t<>	hrond size posside 2	0.00	5.70	No Peak	No Peak (1.5332)				In the second	Tenzaleza la se a	Landaharre	hand the star	I have been a
Image 1 0.00 0.71 10 may model 10 may model 10 may model 10 may model 2000 mage 2000 mage <t< td=""><td>obazani 1 obazani 2</td><td>0.00</td><td>4.93</td><td>No Peak No Peak</td><td>No Peak () No Peak (0.2708)</td><td></td><td></td><td></td><td>DesolkyForezepam 2</td><td>Disnetly Firringepan 1</td><td>Desmaths Electroscopy 2</td><td>Diaspan 1</td><td>Diszepon 2</td></t<>	obazani 1 obazani 2	0.00	4.93	No Peak No Peak	No Peak () No Peak (0.2708)				DesolkyForezepam 2	Disnetly Firringepan 1	Desmaths Electroscopy 2	Diaspan 1	Diszepon 2
Abd/Control Op/Control Op/Contro Op/Control Op/Control <td>mageporn 1</td> <td></td> <td>4.71</td> <td>No Peak</td> <td></td> <td></td> <td>2</td> <td>39.1/140.1 am</td> <td>289.1/226.1 arrs</td> <td>300.1/254.2 amo</td> <td>300.1/1982 anu</td> <td>285.0/193.2 ans</td> <td>285.0/154.1 an</td>	mageporn 1		4.71	No Peak			2	39.1/140.1 am	289.1/226.1 arrs	300.1/254.2 amo	300.1/1982 anu	285.0/193.2 ans	285.0/154.1 an
Schell Markan Open Home Data Markan Data Markan <thdata markan<="" th=""> <thdata markan<="" th=""></thdata></thdata>	onazepam 2						1		3	3	3	1	3
Schell Markan Open Home Data Markan Data Markan <thdata markan<="" th=""> <thdata markan<="" th=""></thdata></thdata>	esalkyifurazepari 2		4,71	No Peak	No Peak (0.4579)		,3		4	.=	6	14	14
Integra Long Long <thlong< th=""> Long <thlong< th=""> <t< td=""><td>esmethythunkrazeparn 1</td><td></td><td>4.55</td><td>No Peak</td><td>No Peak ()</td><td></td><td>1</td><td></td><td>1 I</td><td>ាំ រ</td><td>ľ i</td><td>14</td><td>13</td></t<></thlong<></thlong<>	esmethythunkrazeparn 1		4.55	No Peak	No Peak ()		1		1 I	ាំ រ	ľ i	14	13
standar 6.9 1.47 6.66 661/6 (8.00) Autors 2 Relations 2 <threlations 2<="" th=""> Relations 2</threlations>		5.47	5.47	0.16					i.ditioolifgeteatta	to the Ball of the second second	Landstonthought	and survey	- شيديادية
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	iazepam 2			0.06		1	2	Estabelles 1 95.0/205.0 ans	1statolon 2 295/0/267.1 anno		Hundrazepam 2 334.0/239.1 amu		Florezepan 2 390.2017.1 an
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		0.00			No Peak (1.3693)		10000		1200	1202	1.5	1.2	1.5
Junggen 1 Geo B.0 Big Part II Mark Part II Junggen 1 Geo Geo Big Part III Geo	unitezepen 1	0.00	5.06	No Peak	No Peak ()		1		1		13		
Image 2 00 10	lundazepani 2	0.00	8.16		No Peak (0.4336) No Peak (1)		1		1	13	1	19	19
Distribution 2 Open C10 District distribution District distribution District distribution Open C10 District distribution	lurazepam 2	0.00	8.16	No Peak	No Peak (0.4546)		1	to a Mount of	1	and the fit is	H	the Mostlerine	1
Specific State Operation	ydroxyalprazolam 1 wdroxyalprazolam 2	0.00					Hys	drexy aprazolam 1	Hydroxyabrazolam 2		Hydroxytriazolare 2		Lerazepan 2
Spanny front and an and a spanny front and a sp	ydroxytriazolam 1	0.00	4.10	No Peak	No Peak ()		3	05.1/297.2 ans	325.1/294.9 area	394.0 239.2 amu	359.0(176.0 anus	321.0/273.0 ans	321.0/274.6 am
compon ² 000 C/0 Im/Past More Past (2009) compon ² 000 C/0 Im/Past (2009) Im/Past (2009) compon ² 000 C/0<		0.00		No Peak No Peak	No Peak (0.7382) No Peak (1.		1		1	3	1	1	3
Net Regret 1 Op D1 Implication of the part of the pa	orazepani 2	0.00	4.35	No Peak	No Peak (0.3459)		.4			13	64	1.5	l d
Net Regret 1 Op D1 Implication of the part of the pa		0.00	4.53	No Pleak	No Peak () No Peak (0.0543)		14			1	ra 👘	11	13
Stateging 7 0.00 6.71 No.Page (5064) No.Page (5064) <thno.page (5064)<="" th=""> No.Page (5064) <th< td=""><td>ledazepam 1</td><td></td><td></td><td>No Piezz.</td><td>No Peak ()</td><td></td><td>ticela</td><td>alitheleterner</td><td></td><td>Walkershop and and</td><td>through the second</td><td>1</td><td>1</td></th<></thno.page>	ledazepam 1			No Piezz.	No Peak ()		ticela	alitheleterner		Walkershop and and	through the second	1	1
Characterization Constraint C	ledazepam 2	0.00		No Peak	No Peak (0.6664)			omeratepan 1 35.0/288.0 ans	Lormetatepart 2 337.1/291.1 artis	Medalepan 1 271.0/91.1 anu	Medicepon 2 27L0/207.3 ans	Middanton 1 306.1/291.3 ans	Midatolan 2 326.1/222.0 am
Constraint Open	Noazolari 1 Noazolari 2	0.00	7.62	No Peak No Peak	No Place (0.3435)		1000	00000000000000000000000000000000000000	1	Taxasa a sugar	Talane construction	CONCERNICS OF THE OWNER.	a construction of the second
State Contract Contract <t< td=""><td>itrageport 1</td><td></td><td></td><td>No Peak</td><td></td><td></td><td>1</td><td></td><td>1</td><td>area a</td><td></td><td></td><td></td></t<>	itrageport 1			No Peak			1		1	area a			
Sintegran Life					13		1		13	10		13	12,
Stategye1 4/3 1/3 6/17/2/5/303 6/17/2/5/303 Consegure 2 Nucleyes 2 Nucleyes 3 Consegure 1 State 6.00 6.00 100	ordiazepam 2	4.96	4.90	64.20		1	1	FRAAX 22	1. Jacob	i i			A and the second second
magent 1 0.00 6.15 In Pract (1) De Pract (1) magent 2 0.00 6.15 In Pract (1) De Pract (1) De Pract (1) magent 2 0.00 6.15 In Pract (1) De Prac (1) De Pra		4.23	4.23	20.30	()			Nitratepan 1	Nitrazepan 2	Nordiazepan 1	Noodiazepan 2	Ovazepan 1	Osazepan 2
Sector A71 A71<	nazepare 1			NO PRAK			2	\$2.0°236.1 ams	282.0/190.2 amu	27L.03402 amo	271.1/1649 ans	287.0/24L1 ans	287.0/268.9 am
λ λ λ δ.71 6.67 0.670 6.671 0.6700 / 0.000m1 0.00 4.67 10 Print 10/2 1 <td>azepam 2</td> <td></td> <td></td> <td>his Peak</td> <td>No Peak (0.0721)</td> <td></td> <td>3</td> <td></td> <td>1</td> <td>1</td> <td>1</td> <td>1</td> <td>3</td>	azepam 2			his Peak	No Peak (0.0721)		3		1	1	1	1	3
200000 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	imazopam 2	4.71	4.71	49.00	0.6771 (0.6598)	1	.1			-		Li î	Lá –
Bit Depart Bit Depart No Post () No Post () Post () <td>iazolam 1</td> <td>0.00</td> <td></td> <td>No Peak</td> <td>No Peak (1)</td> <td></td> <td>11</td> <td></td> <td>9</td> <td>1</td> <td>18</td> <td>19. A</td> <td>19</td>	iazolam 1	0.00		No Peak	No Peak (1)		11		9	1	18	19. A	19
読む 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					No Peak (0.8312)				1	Incariant former		Unangonada	Lenneter by
ppdam1 0.00 7.04 Na Pauk RePeak ()	alepion 2	0.00	4.35	No Peak	No Peak (0.7393)			Prozepan 1	Prazepan 2	Temazoan 1	Tematepan 2 100 L/2572 area	Triazelan 1	Trisorden 2 340.0/314.9 am
	olpidem 1	0.00	7.04	No Pleas	No Peak ()			and a real of the	ARX P 1947 0 MIN	211.0.023.1.480	20020273100	240.4.2003 GB	
	olpidem 2 opicibne 1			NO PNAK	No Pees ()	<u> </u>							
ppbbme 2 0.00 5:03 No Peak (1:000)	spictore 2	0.00	5.09	No Peak	No Peak (1.0009)								
					0								

Figure 5. Example report generated automatically by Cliquid[™] Drug Screen & Quant Software of a urine sample tested positive for benzodiazepines (1.6ng/mL Diazepam, 670ng/mL Nordiazepam, and 470ng/mL Temazepam).

Authors

André Schreiber Applied Biosystems Concord, ON (Canada), Houssain El Aribi and John Gibbons MDS SCIEX Concord, ON (Canada).

Acknowledgements

The authors would like to thank Warren Walsh (SickKids Hospital Toronto, Canada) for the donation of forensic urine samples.

References

- S. Hegstad, E.L. Øiestad, U. Johansen, and A.S. Christophersen: J. Anal. Toxicol. 30 (2006) 31-37
- M. Laloup, M. Fernandez, G. Boeck, M. Wood, V. Maes, and N. Samyn: J. Anal. Toxicol. 29 (2005) 616-626
- H. Belva-Besnet, B. Casetta,
 M. Gravier, and D. Olichon:
 Application Note
 Applied Biosystems (2005)
 #114AP39-01
- 4 Cliquid[™] Drug Screen & Quant
 Software Product Note
 Applied Biosystems (2007)
 #114PB18-01

For Forensic Use Only. Not for use in diagnostic procedures.

© 2007 Applera Corporation and MDS Inc. All Rights Reserved. Applera, Applied Biosystems and AB (design) are registered trademarks of Applera Corporation or its subsidiaries in the US and/or certain other countries. Cliquid and Turbo V are trademarks and QTRAP and LINAC are registered trademarks of Applied Biosystems/MDS SCIEX, a joint venture between Applera Corporation and MDS Inc. All other trademarks are the sole property of their respective owners.

Printed in the USA. 09/2007 Publication 114AP66-01



Headquarters

850 Lincoln Centre Drive | Foster City, CA 94404 USA Phone 650.638.5800 | Toll Free 800.345.5224 www.appliedbiosystems.com

International Sales

For our office locations please call the division headquarters or refer to our Web site at www.appliedbiosystems.com/about/offices.cfm